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Abstract
Patients with schizophrenia and their siblings typically show subtle changes of brain structures, such as a reduction of
hippocampal volume. Hippocampal volume is heritable, may explain a variety of cognitive symptoms of schizophrenia and
is thus considered an intermediate phenotype for this mental illness. The aim of our analyses was to identify single-
nucleotide polymorphisms (SNP) related to hippocampal volume without making prior assumptions about possible
candidate genes. In this study, we combined genetics, imaging and neuropsychological data obtained from the Mind
Clinical Imaging Consortium study of schizophrenia (n = 328). A total of 743,591 SNPs were tested for association with
hippocampal volume in a genome-wide association study. Gene expression profiles of human hippocampal tissue were
investigated for gene regions of significantly associated SNPs. None of the genetic markers reached genome-wide
significance. However, six highly correlated SNPs (rs4808611, rs35686037, rs12982178, rs1042178, rs10406920, rs8170) on
chromosome 19p13.11, located within or in close proximity to the genes NR2F6, USHBP1, and BABAM1, as well as four SNPs
in three other genomic regions (chromosome 1, 2 and 10) had p-values between 6.7561026 and 8.361027. Using existing
data of a very recently published GWAS of hippocampal volume and additional data of a multicentre study in a large cohort
of adolescents of European ancestry, we found supporting evidence for our results. Furthermore, allelic differences in
rs4808611 and rs8170 were highly associated with differential mRNA expression in the cis-acting region. Associations with
memory functioning indicate a possible functional importance of the identified risk variants. Our findings provide new
insights into the genetic architecture of a brain structure closely linked to schizophrenia. In silico replication, mRNA
expression and cognitive data provide additional support for the relevance of our findings. Identification of causal variants
and their functional effects may unveil yet unknown players in the neurodevelopment and the pathogenesis of
neuropsychiatric disorders.
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Introduction
Despite a number of twin studies indicating high heritability in
complex neuropsychiatric disorders such as schizophrenia [1–4],
the underlying molecular pathways and mechanisms of suscepti-
bility for these disorders remain elusive. A major issue in
psychiatric genetics is the lack of replication of putative risk
variants [5–7]. Possible reasons for this problem might include the
previously widely used candidate gene approach, polygenic
inheritance, the genetic and the phenotypic heterogeneity of the
disorders, and the low reliability and long-term stability of
psychiatric diagnoses.
To address the latter, it has been suggested to use intermediate
phenotypes instead of diagnosis, because intermediate phenotypes
are thought to be more proximal to the underlying substrate of the
illness than the varying clinical constructs. Suitable intermediate
phenotypes are traits that are reliably measurable, stable,
continuously distributed (so called ‘‘quantitative traits’’), heritable,
and disease-associated [8,9].
In patients with schizophrenia, a reduction of hippocampal
volume has been repeatedly demonstrated [10–13]. Abnormalities
of the structure and function of the hippocampus in schizophrenia
have been associated with deficits in memory and executive
function [14], suggesting that these structural changes could reflect
a central pathophysiological process associated with the disease
[11]. Furthermore, sibling and family studies provide evidence for
the heritability (40–70%) of this brain structure [15,16]. There-
fore, it is widely acknowledged that hippocampal volume
represents a reliable intermediate phenotype for schizophrenia.
With the rapid development of genotyping technology, genome-
wide association studies (GWAS) offer the opportunity to identify
biological markers and risk genes that are associated with specific
phenotypes by scanning the entire genome. Whereas candidate
gene approaches rely on prior and possibly ill-defined assumptions
about the underlying biological pathways and neurodevelopmental
models of disorders or intermediate phenotypes, a GWAS
approach is hypothesis-free.
After the identification of new risk genes, it is crucial to elucidate
the function of the genetic variants and their potential contribution
to the phenotype or illness. The analysis of gene expression profiles
may provide insights into the underlying genetic mechanisms
influencing a phenotype. This can be achieved by examining the
differential allelic expression of gene products in the same region,
which provides additional evidence for the functional relevance of
the findings [17,18]. A complementary strategy is to study the
relationship of risk variants to cognitive or behavioural measures
which are closely linked to the brain-based phenotype [19].
By combining the power of a GWAS with the use of a well-
established brain-based intermediate phenotype we aimed to
identify relations between genetic polymorphisms and the
hippocampal volume of patients with schizophrenia and demo-
graphically similar healthy control subjects. We sought replication
of our findings using the very recently published data of the
Enhancing Neuro Imaging Genetics through Meta-Analysis
(ENIGMA) Consortium [20] and data of the IMAGEN study, a
large European multicentre genetic-neuroimaging study of rein-
forcement behavior in adolescence [21]. An additional aim was to
determine possible functional mechanisms of the identified genetic
associations by analyzing (a) differential allelic expression using
gene expression data from human hippocampus tissue and (b) the
relation of risk variants to hippocampus-dependent cognitive
functioning.
Materials and Methods
Participants
The Mind Clinical Imaging Consortium (MCIC) study of
schizophrenia [13,22] obtained baseline structural MRI scans on
a total of 328 subjects from four participating sites: Massachusetts
General Hospital in Boston (MGH) and the Universities of Iowa
(UI), Minnesota (UMN) and New Mexico (UNM). All subjects
gave written informed consent prior to study enrolment. The
human subjects research committees at each of the four sites
(Massachusetts General Hospital in Boston and the Universities
of Iowa, Minnesota and New Mexico) approved the study
protocol. We confirm that all potential participants who declined
to participate or otherwise did not participate were eligible for
treatment (if applicable) and were not disadvantaged in any other
way by not participating in the study. During the consent process
the subjects were asked a series of questions to assure that they
understood the nature of the study, that if they chose to
participate it was voluntary and that they could stop at any time
without affecting their care, and that they understood the risks
and benefits of the study. If they stated that they wanted to
participate, they were also asked the reason why they chose to
participate. If there was any question as to the ability to provide
informed consent (i.e., they don’t understand the risks or benefits,
or they suffer from acute delusions that could significantly impair
a patient’s judgment) then they were not recruited for the study.
In addition, if during the clinical interview it was determined that
they lacked the ability to provide informed consent, then they
were dropped from the study at that time. The patient group (SZ)
consists of subjects with a DSM-IV diagnosis of schizophrenia,
established using structured clinical interviews and review of case
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files by trained clinicians. Healthy controls (HC) were included if
they had no history of a medical or Axis I psychiatric diagnosis.
All participants were required to be at least 18 years of age and
no older than 60 and to be fluent in English. Participants were
excluded if they had a history of neurologic disease, or psychiatric
disease other than schizophrenia, history of a head injury with
loss of consciousness, history of substance abuse or dependence
within the past month, severe or disabling medical conditions,
contraindication to MR scanning or IQ less than 70 (based on the
reading subtest from the WRAT3). The final sample with
complete and high-quality structural MRI and genetic data
comprised of 126 HC and 115 SZ. For quality assurance
procedures see below.
For replication purpose we obtained additional genetic and
sMRI data from participants of (I) the ENIGMA network [20]
with a discovery sample of N = 7,795 (including 5,775 healthy
individuals and 2,020 patients with depression, anxiety, Alzhei-
mer’s disease or schizophrenia), and (II) the IMAGEN study [21]
containing N = 1,663 healthy 14-year old adolescents (for detailed
information see Supporting Information (SI) 1.1. in File S1).
Clinical Measures
Prior to subject enrolment, clinicians from all four MCIC sites
participated in a two-day training session, during which cross-
site inter-rater reliability for the primary diagnostic and
symptom-rating scales was established (.85% concordance
with videotaped training materials). All study participants
underwent an extensive clinical diagnostic assessment that
included either the SCID-I/P or NP [23] or the Comprehensive
Assessment of Symptoms and History (CASH) [24]. Premorbid
cognitive achievement was estimated by the Wide Range
Achievement Test (WRAT3-RT) [25]; parental socioeconomic
status (SES) was determined using the Hollingshead index [26]
and handedness was determined using the Annett Scale of Hand
Preference [27]. Severity of positive and negative symptoms
were rated using the Scale for the Assessment of Positive
Symptoms (SAPS) and the Scale for the Assessment of Negative
Symptoms (SANS) [28,29]. Antipsychotic history was collected
as part of the psychiatric assessment using the PSYCH
instrument [30] and cumulative and current antipsychotic
exposure was calculated using the chlorpromazine (CPZ)
conversion factors [31]. See Table 1 and Table S1 in File S1
for detailed information.
Structural Image Acquisition
MCIC structural MRI data were acquired with either a 1.5T
Siemens Sonata (MGH, UI, UNM) or a 3T Siemens Trio (UMN).
The T1-weighted structural brain scans at each of the four sites
were acquired with a coronal gradient echo sequence:
TR = 2530 ms for 3T, TR = 12 ms for 1.5T; TE = 3.79 for 3T,
TE = 4.76 ms for 1.5T; TI = 1100 for 3T; Bandwidth = 181 for
3T, Bandwidth = 110 for 1.5T; 0.62560.625 voxel size; slice
thickness 1.5 mm; FOV, 25662566128 cm matrix;
FOV = 16 cm; NEX = 1 for the 3T, NEX = 3 for the 1.5T. Cross
site MRI acquisition calibration and reliability were established in
a preceding study using human phantoms, following guidelines
developed by the biomedical informatics research network (BIRN)
test bed for morphometry [32,33].
Structural Image Data Processing
MCIC structural MRI data from three consecutive volumes
were registered, motion corrected, averaged and analyzed in an
automated manner with atlas-based FreeSurfer software suite
(http://surfer.nmr.mgh.harvard.edu, Version 4.0.1). This process
included volumetric segmentation, cortical surface reconstruction
[34–37] and the estimation of total intracranial volume (ICV) [38].
Hippocampal volume is a standard output of the FreeSurfer
volumetric segmentation [35]. Previous imaging genetics studies
have shown the same genetic effects for the left and right
hippocampus [39,40]. Therefore we used mean hippocampal
volume (averaged across the right and left hemisphere) as the
primary parameter for analysis. Segmentation and surface
reconstruction quality were assured by manual inspection of all
raw MRI volumes, segmented volumes in three planes and pial as
well as inflated volumes. Five participants’ MRI data failed the
aforementioned quality assurance. The data of these subjects were
then recovered with minor manual intervention following the
FreeSurfer user guidelines.
Genotyping
Blood samples were obtained of each MCIC participant and
sent to the Harvard Partners Center for Genetics and Genomics.
DNA extraction and genotyping was performed according to the
manufacturer’s protocol and blinded for group assignment (SI 1.2.
in File S1). Genotyping was performed at the Mind Research
Network (MRN) Neurogenetics Core Lab using the Illumina
HumanOmni-Quad BeadChip interrogating 1,140,419 SNPs.
Table 1. Demographic variables of the MCIC sample.
Scanner
Fieldstrength Sample
Sex
(female)
Ethnicity
(White) Age (years) WRAT3-RT Parental SES Handedness
Hippocampal
Volume
N N % N % mean SD mean SD mean SD mean SD mean SD
1.5T HC 107 42a 39.3 80 74.8 32.07b 10.83 50.96b 4.05 2.76 0.71 0.81 2.51 8814.80b 859.13
SCZ 85 22a 25.9 55 64.7 35.91b 11.10 46.56b 7.06 2.92 1.04 1.28 3.34 8318.12b 989.96
3T HC 19 7 36.8 17a 89.5 31.89 11.26 51.00b 3.94 2.37 0.76 0.47 0.77 8929.00b 817.21
SCZ 30 8 26.7 18a 60.0 32.43 10.45 45.97b 6.09 2.63 0.85 1.67 3.43 8328.13b 849.54
Total HC 126 49a 38.9 97a 77.0 32.05b 10.85 50.97b 4.02 2.70 0.73 0.76 2.33 8832.02b 850.75
SCZ 115 30a 26.1 73a 63.5 35.00b 11.01 46.40b 6.79 2.84 0.99 1.38 3.35 8320.73b 951.70
Means and standard deviations (SD) are given. HC= healthy control, SZ = patient with schizophrenia. Ethnicity was defined as described under Methods. WRAT3-
RT =Wide Range Achievement Test 3 – Reading Test. Parental SES (socioeconomic status) was classified according to Hollingshead, and handedness determined using
the Annett Scale of Hand Preference.
asignificantly different between HC and SZ on basis of Chi-Square (p,0.05).
bsignificantly different between HC and SZ on basis of Welch (p,0.05).
doi:10.1371/journal.pone.0064872.t001
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Normalized bead intensity data obtained for each sample were
loaded into GenomeStudio2010 software, which generated SNP
genotypes from fluorescent intensities using the manufacturer’s
default cluster settings. The raw genotypic data were imported into
a genome-wide data management system (Laboratory Information
Management System) to allow the tracking of individual samples,
quality control and the export of user defined formats compatible
with the genetic programs used for statistical analysis.
Quality control steps included a per-individual quality control,
i.e. identification and exclusion of individuals with a) discordant
sex information, b) missing genotype information of more than
5%, c) unusual heterozygosity rate (details see below), d) divergent
ancestry (see paragraph about population stratification below) and
e) duplicated or related individuals, and a per-marker quality
control (identification and exclusion of SNPs with f) an excessive
missing genotype rate of more than 10%, g) significantly different
missing genotype rates between cases and controls, and h) a minor
allele frequency below 5%) [41,42]. All steps were carried out in
PLINK [43]. For the initial 255 samples, the total genotyping rate
was 99.8%. Sex was estimated based on SNP data and was in line
with self-disclosure. Due to excess heterozygosity we excluded two
control samples (outliers defined as mean heterozygosity +/
24SD). Testing for random (call rate ,90%) and non-random
missing genotype data (haplotypic case/control test with
p,1610210) led to the exclusion of 657 SNPs. Another 194,543
SNPs were excluded because of a minor allele frequency less than
0.05, resulting in a final dataset of 743,591 autosomal SNPs.
Statistics
For each of the 743,591 SNPs tested for association in the
MCIC sample, we used PLINK [43] to fit a linear regression
model with minor allele count, sex, age, diagnosis, ICV and
scanner field strength as predictors of total hippocampal volume.
We modeled the effects of diagnosis (i.e. healthy individual or
participant with schizophrenia) to account for non-random
sampling and possible additional environmental factors specific
to psychiatric patients such as treatment effects or stress.
As population stratification is a well-known issue in heteroge-
neous data sets and can become problematic especially in
association studies, we needed to correct for allele frequency
differences that are due to systematic ancestry differences. We
applied principal component analysis (PCA) to our genotype data
using EIGENSTRAT of the EIGENSOFT 3.0 software package
[44,45]. Before PCA, SNP data were pruned based on LD as
recommended [46]. We also excluded autosomal SNPs, SNPs in
problematic regions of long-range linkage disequilibrium (LD) (as
recommended by Price et al. [47]), and all SNPs in a +/2500 kb
range of SNPs found in the ‘‘GWAS Catalog’’ (http://www.
genome.gov/admin/gwascatalog.txt, accessed on 21/6/11) to be
possibly associated with hippocampal volume or schizophrenia,
resulting in 103,860 SNPs. The first 10 principal components
(based on Tracy-Widom-Statistic, see Table S2 in File S1) were
used as additional covariates in our regression model (see above).
To verify our results in an ethnically homogeneous sample we
defined a subsample based on stringent criteria, including
individuals of European descent only. For this purpose, we again
performed EIGENSTRAT-based PCA using the pruned SNP set
as defined above to analyze our sample in combination with four
HapMap populations (CHB = Han Chinese in Beijing, China,
JPT = Japanese in Tokyo, Japan, YRI = Yoruba in Ibadan,
Nigeria, and CEU = Utah residents with ancestry from northern
and western Europe; International HapMap Project http://www.
hapmap.org/). Based on this analysis, a homogeneous subsample
of individuals close to the CEU cluster was selected, (n = 170; see
SI 1.3 in File S1 and Figure S1 for further details).
Replication Analyses
For replication, we chose all top-ranking SNPs of our MCIC
association analysis, i.e. markers with p-values smaller than 1025.
We then checked for association signals with bilateral hippocam-
pal volume for the aforementioned SNPs (if available) and all other
available intragenic SNPs in a window of +/2100 kb of our top
SNPs (I) using EnigmaVis, an online interactive visualization tool
of genome-wide association signals of the ENIGMA study [48],
and (II) estimating similar linear regression models as described
above using the IMAGEN data.
Differential Allelic Expression in Human Hippocampus
Biopsy samples were obtained from 142 patients with chronic
pharmacoresistant temporal lobe epilepsy. After quality control,
fresh frozen human hippocampal segments of 138 individuals were
prepared as tissue slices under cryostat conditions (Bonn tissue
bank) and total DNA and RNA were isolated using AllPrep DNA/
RNA Micro Kit (Qiagen, Hilden, Germany). A volume of 50 ng of
total RNA was amplified (Illumina TotalPrep 96-RNA Amplifi-
cation Kit, Ambion/Applied Biosystems, Darmstadt, Germany)
and labelled cRNA was hybridised to Illumina human HT-12
Expression v3 BeadChips (Illumina, San Diego, CA, USA). All
expression profiles were extracted using GenomeStudio software
(Illumina). For genome-wide SNP-genotyping of these individuals,
200 ng of DNA were hybridised to Illumina Human660W-Quad
v1 DNA Analysis Bead-Chip (Infinium HD Assay Super manual,
Illumina).
The sequences of expression probes were re-aligned to UCSC
version 18 (hg18, http://genome.ucsc.edu/) allowing only perfect
matches, and then normalized using the vsn2 option implemented
in the package ‘VSN’ for R. For quantitative trait analysis, linear
regression of an additive allelic model predicting mRNA
expression was performed using the GenABEL package for R
(http://www.genabel.org/), including the covariates gender, age
at sampling, and the first five components resulting from
multidimensional scaling analysis of the genotype data carried
out in PLINK [43]. For further details see SI 1.4. in File S1 and
[17].
Association with Hippocampus-dependent Cognitive
Functioning
To test for possible effects of single putative genetic risk variant
(identified in the MCIC sample using the linear regression models
described above) on hippocampus-dependent cognitive function-
ing we applied structural equation modeling (SEM) following the
guidelines set forth by Arbuckle and Wothke (1999) using AMOS
18.0 with full maximum likelihood estimation. We hypothesized
that the risk polymorphism would have an indirect negative effect
on memory functioning, which would be mediated via hippocam-
pal volume. ‘‘Memory’’, the dependent variable, was designed as a
latent variable defined by two different neuropsychological
measures tapping hippocampus-dependent memory-functions
(see SI 1.5. in File S1) which were available for 198 subjects.
For reasons of simplicity, we included only the first two most
significant principal components (see above; Table S2 in File S1)
to correct the independent variable – the genetic polymorphism –
for population stratification. Hippocampal volume (adjusted for
the effects of ICV and scanner field strength) was specified as
mediator variable and we explicitly modeled the effects of age, sex
and diagnosis on hippocampal volume and memory.
GWAS of Hippocampal Volume in Schizophrenia
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Results
Sample characteristics
MCIC patients and controls did not differ significantly in
parental socioeconomic status or handedness. Patients were
slightly older, less likely to be female, included fewer
participants of European descent, had lower WRAT3-RT
scores and, as expected, a significantly smaller mean hippo-
campal volume (Table 1). For an overview of the clinical
variables of the patient group see Table S1 in File S1. We also
found no differences in demographic or clinical variables when
stratifying the sample according to the acquisition site-specific
scanner field strength.
GWAS
We tested each of the 743,591 SNPs in the MCIC sample using
multiple linear regression models for association with human
hippocampal volume as described above. Figure 1 shows the
quantile-quantile (QQ) plot. An inflation factor of l= 0.998 was
estimated, indicating that there is no inflation of false-positive
results derived from genotyping errors or uncontrolled population
stratification. No marker exceeded the widely acknowledged
genome-wide significance threshold of 561028 [49].
Assuming that the most significantly associated SNPs comprise
variants which are actually influencing hippocampal volumes, in
the following we focus on the ten loci having p-values smaller than
161025. The smallest p-value (p = 8.361027) was obtained for
Figure 1. Quantile-quantile plot for MCIC association results. The empirical and theoretical distributions are shown as dots and line,
respectively.
doi:10.1371/journal.pone.0064872.g001
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SNP rs35686037, which is located 3,384 bases upstream of NR2F6
(nuclear receptor subfamily 2 group F member 6) and 1,314 bases
downstream of USHBP1 (Usher syndrome 1C binding protein 1)
on chromosome 19. Furthermore, we found four associated
markers with a p-value smaller than 161025 on chromosome 1
(within KIF26B), 2 (within or near TRPM8) and 10 (LOC283089).
An overview of the top-SNPs and corresponding gene regions is
shown in Table 2; a Manhattan plot of the p-values is shown in
Figure 2. Additional information about the distribution of
genotypes, call rate, and heterozygosity rates can be found in
Table S3 in File S1, regression coefficients, standard errors and
corresponding confidence intervals for each of the ten SNPs are
given in Table S4 in File S1 and Figure S2.
There were no significant pairwise relationships between the
ten gene loci and either sex, ethnicity, age, WRAT3-RT scores,
parental SES or handedness (data not shown). We also inspected
the results for association with left and right hippocampal
volume separately. Additionally, we tested for association with
hippocampal volume in a model without covarying for
diagnostic status (Table S5 in File S1) and in a homogeneous
subsample of individuals with ancestry from north-western
Europe (defined as described above; see also SI 1.3. in File S1).
As can be seen in Table S5 in File S1 and in Table 3, all ten loci
showed again significant effects with p-values smaller than
5.561024 and the direction of the effects was the same.
Furthermore, we tested for association with hippocampal
volume in a subsample of only patients and only healthy
controls, respectively. All ten SNPs exceeded nominal signifi-
cance in each group and again, the direction of these effects
were the same (Table 3).
The strongest evidence for association in our main analysis as
well as in subsequent analyses (see above) was found for six highly
correlated SNPs (rs4808611, rs35686037, rs12982178,
rs10424178, rs10406920, and rs8170) on chromosome 19. The
LD structure of these six markers is shown in Figure 3. The
genomic region, characterized by high LD, includes three genes:
NR2F6, USHBP1, and BABAM1 (BRISC and BRAC1 A complex
member 1; also referred to as C19orf62). Rs8170 is the only SNP (of
all SNPs with p,161025) located in a coding region (coding-
synonymous K (AAG)RK (AAA)).
For the most significant SNP in this LD block (rs35686037) we
found a reduction in hippocampal volume of approximately 5%
per risk allele (,391 mm3 compared to the mean hippocampal
volume of 8588 mm3). This corresponds to an effect size of
Cohen’s f2 = 0.115 and an explained variance of 5.72% (calculated
as explained variance in addition to the variance explained by the
control variables in the linear model).
Using the in silico replication strategy outlined above, we found
the following significant association signals in the genomic
neighborhood (+2100 kb) of our main hits: In close proximity
of rs9919234 on chromosome 1 we found 17 SNPs associated with
hippocampal volume (e.g. rs1472051 with p = 8.761023) in the
ENIGMA sample, and two SNPs in the IMAGEN sample, all
belonging to the same gene (KIF26B). On chromosome 2 we found
20 associated SNPs (e.g. rs763379 with p = 9.261023; 2 kb
upstream of rs17866592) in the ENIGMA sample, and three
other SNPs (e.g. rs617970 with p = 3.261024) in the IMAGEN
sample. Each of these SNPs is located in the same or in the
adjacent gene (TRPM8, SPP2) or the intergenic region between
those two genes. Close to rs1254152 on chromosome 10 we
identified 31 SNPs in association with hippocampal volume (e.g.
rs7911084 with p = 1.461023) in the ENIGMA sample, and
rs12570141 with p = 2.961022 in the IMAGEN sample. For the
interconnected genomic region on chromosome 19 we searched a
wider window (300 kb) and found 12 associated SNPs (e.g.
rs4808629 with p = 3.561023) in the ENIGMA sample, and 12
further SNPs (e.g. rs2278897 with p = 5.161024) in the IMAGEN
sample, all close to our top-ranking SNPs rs480811, rs35686087 or
rs8170. An overview of all relevant SNPs is given in Table S6 and
S7 in File S1.
Differential Allelic Expression in Human Hippocampus
Only five of our ten main findings were part of the differential
allelic expression analysis in human hippocampus tissue
(rs9919234, rs17866592, rs1254152, rs4808611, rs8170). Howev-
er, based on LD (Figure 3) the latter two SNPs were identified to
function as the most relevant proxies for the missing SNPs on
chromosome 19 and rs17866592 can serve as proxy for
rs11901004 on chromosome 2 (r2 = 1). In a cis-region of the six
markers of chromosome 19 (defined using a window of +21 mega
Table 2. Genome-wide association results for SNPs associated with hippocampal volume in the MCIC sample.
SNP CHR BP A1 A2 MAF BETA STAT P Gene/Region
rs9919234 1 243770613 G T 0.4046 310.6 4.742 3.766610206 KIF26B (intron)
rs11901004 2 234591999 T G 0.1287 2436.6 24.686 4.885610206 TRPM8 (UTR 39)
rs17866592 2 234594425 C T 0.1354 2446.7 24.851 2.305610206 TRPM8 (1,521 bases
downstream)
rs1254152 10 122572603 G A 0.3880 307.9 4.688 4.798610206 LOC283089 (intron)
rs4808611 19 17215825 T C 0.1743 391.2 4.692 4.711610206 NR2F6 (intron)
rs35686037 19 17220535 T C 0.1680 431.8 5.071 8.305610207 USHBP1 (1,214 bases
downstream)
rs12982178 19 17232568 C T 0.1896 416.3 5.015 1.083610206 USHBP1 (intron)
rs10424178 19 17240558 T C 0.2095 390.8 4.909 1.761610206 BABAM1 (intron)
rs10406920 19 17250648 T C 0.1805 376.1 4.610 6.750610206 BABAM1 (intron)
rs8170 19 17250704 A G 0.1805 376.1 4.610 6.750610206 BABAM1 (coding-synon)
SNP IDs with chromosome (CHR), basepair position (BP), minor (A1) and major allele (A2), minor allele frequency (MAF), regression coefficient (BETA), coefficient (STAT)
and asymptotic p-value for t-statistic, and corresponding gene regions: KIF26B (kinesin family member 26B), TRPM8 (transient receptor potential cation channel,
subfamily M, member 8), LOC283089 (uncharacterized), NR2F6 (nuclear receptor subfamily 2, group F, member 6), USHBP1 (Usher syndrome 1C binding protein 1), and
BABAM1 (BRISC and BRCA1 A complex member 1). For additional information see Table S3 in File S1.
doi:10.1371/journal.pone.0064872.t002
GWAS of Hippocampal Volume in Schizophrenia
PLOS ONE | www.plosone.org 6 June 2013 | Volume 8 | Issue 6 | e64872
basepairs (Mb)) we identified the minor alleles of rs4808611 and
rs8170 (as well as of rs35686037, rs12982178, rs10424178 and
rs10406920 based on LD) to be highly associated with lower
expression of ABHD8 and MRPL34 (p = 2.761025 and
p = 7.661025, respectively; Bonferroni-corrected for the number of
transcripts in the cis-region). Both genes are in head-to-head
orientation to each other and located ca. 0.12 Mb downstream of
BABAM1.
Figure 2. Genome-wide association results of hippocampal volume in the MCIC sample. Negative logarithmic p-values are plotted against
their genomic position.
doi:10.1371/journal.pone.0064872.g002
Table 3. P-values of 10 MCIC major findings in subanalyses.
SNP CHR LeftHippoVol RightHippoVol
Subset of European
descent Group of SZ patients Healthy controls
rs9919234 1 1.705610206 5.425610205 5.011610205 1.572610203 5.848610204
rs11901004 2 4.055610205 5.126610206 5.551610204 5.115610204 5.780610203
rs17866592 2 1.146610205 4.761610206 4.727610204 2.560610204 3.614610203
rs1254152 10 8.934610206 2.101610205 3.835610204 1.743610204 5.290610203
rs4808611 19 7.865610206 2.274610205 3.315610204 2.216610202 6.033610206
rs35686037 19 1.370610206 5.589610206 7.826610205 1.381610202 1.155610206
rs12982178 19 2.847610206 4.763610206 7.515610205 3.943610202 1.477610207
rs10424178 19 1.688610206 1.618610205 3.319610205 2.893610202 1.676610206
rs10406920 19 7.452610206 4.321610205 3.740610204 1.434610202 4.289610205
rs8170 19 7.452610206 4.321610205 3.740610204 1.434610202 4.289610205
Association with left and right hippocampal volume and association with hippocampal volume in a MCIC subsample of European descent was analyzed controlling for
the same variables as in our main GWAS models. Association of hippocampal volume in a group of only patients with schizophrenia (N = 115) or only healthy controls
(N = 126) was controlled for gender, scanner field strength differences, age, and ICV.
doi:10.1371/journal.pone.0064872.t003
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Association with Hippocampus-dependent Cognitive
Functioning
In order to explore possible indirect effects of risk polymor-
phisms on memory functioning we compared different structural
equation models: Model 1 did neither include SNP nor
hippocampus effects on memory, Model 2 comprised direct SNP
effects on memory but no effects of hippocampus and finally
Model 3 included direct effects of SNP on hippocampus as well as
direct effects of hippocampus on memory (Figure S3). The
comparison of established model fit indices [50] and information
criteria [51,52] revealed Model 3 as the best fit (Table S6 in File
S1). In this model the negative effect of risk alleles on memory
functioning are mediated by hippocampal volume. The size and
direction of all effects are depicted in Figure S3 for SNP
rs35686037, while the negative indirect effects of each of the six
genetic risk variants of chromosome 19 are listed in Table S8 in
File S1.
Discussion
By performing genome-wide association analyses of an inter-
mediate phenotype, we identified novel genetic loci that are
associated with hippocampal volume, as measured by MRI in
patients with schizophrenia and in healthy controls. Six highly
correlated SNPs in a LD block on chromosome 19p13.11 and four
SNPs in three genomic regions on chromosome 1, 2 and 10
showed p-values between 6.761026 and 8.361027 in the GWA
models. The SNPs on chromosome 19 were strongly associated
with altered gene expression in human hippocampus tissue.
Furthermore, our in silico replication analysis, using large datasets
of the ENIGMA study and IMAGEN studies, provides supporting
evidence for our association results.
Due to the clustering of our findings in the chromosome 19
region (providing additional support for the validity of these
findings), we will first discuss these six SNPs. The genes
corresponding to the aforementioned SNPs on chromosome
19p13.11 are protein-coding and feature a direct or indirect
association with hippocampus and brain development. NR2F6 is
an orphan nuclear receptor also known as EAR2. It has been
shown to influence DNA binding, ligand-dependent nuclear
receptor activity, zinc ion binding, sequence specific DNA binding
transcription factor activity and hormone receptor activity [53,54].
Furthermore, NR2F6 is involved in neural development, signal
transduction and as a co-regulator of thyroid hormone nuclear
receptor and glucocorticoid receptor functioning [55]. The latter
function involves physical and functional interactions with NR3C1,
a glucocorticoid receptor, which plays a major role in regulation of
the hypothalamic-pituitary-adrenocortical (HPA) system. Gluco-
corticoids exert negative feedback control on the HPA axis by
regulating hippocampal and paraventricular nucleus neurons [56].
Oversecretion of glucocorticoids caused by sustained stress can
damage the feedback response and cause hippocampal atrophy
[57,58]. Genetic variants in NR3C1 variants contribute to the
genetic programming of the individual’s set point of HPA axis
activity and may be involved in the deregulation of HPA axis
activity by biological or psychosocial stress, trauma, and early life
experiences [56]. Accordingly, NR3C1 variants have been
associated with hippocampal volume and unipolar depression
[59].
BABAM1 plays a role in DNA repair and chromatin modifica-
tion [60] and USHBP1 interacts via its C-terminus with the first
PDZ domain of the Usher syndrome 1C protein, which is coded
by one of several genes responsible for the Usher syndrome - a
relatively rare genetic disorder that is a leading cause of deafness
and gradual blindness [61]. These genes have important functions
in the development and stability of the cell layers of the retina. The
retina is a part of the central nervous system (and often used as a
model in developmental brain cell culture studies) and it may thus
be speculated whether genetic variants in USHBP1 are associated
with developmental abnormalities in the arrangement of neurons
in cell layers in other brain regions, such as the hippocampus, as
well.
According to the Allen Brain Atlas (Allen Institute for Brain
Science; http://human.brain-map.org/) all three genes (NR2F6,
USHBP1, BABAM1) in the highly associated LD block on
chromosome 19 are expressed in human brain. As an example,
the expression of NR2F6 in human hippocampus is shown in
Figure S4. Furthermore, we could show that SNPs in the
aforementioned genes influence the expression of proximal genes
in human resected hippocampi in an allele-wise manner. The
newly identified risk variants in NR2F6, USHBP1, and BABAM1
are associated with the expression of ABHD8 (abhydrolase domain
containing 8), important for hydrolase activity [62], and MRPL34
(mitochondrial ribosomal protein L34), a structural constituent of
ribosomes and relevant in translation processes [63]. Our findings
of differential allelic expression underline the importance of the
identified loci for the expression of genes related to protein
synthesis and thus could provide a functional understanding of our
genetic association results.
The identified polymorphisms and the corresponding genes
NR2F6, USHBP1 and BABAM1 have not previously been
associated with schizophrenia or other neuropsychiatric disorders.
Given that our imaging genetics approach is very different from
comparing genotypes across cases and controls this is not
surprising. However, since hippocampal volume is a well
acknowledged intermediate phenotype for schizophrenia our
results open up new avenues for psychiatric research. The fact
that the effect of the identified genetic variants on hippocampal
Figure 3. Linkage disequilibrium (LD) plot of all MCIC main hits
on chromosome 19. LD is given based on r2 estimated using the
current dataset. Each diamond indicates the pairwise magnitude of LD,
with dark grey/black indicating strong LD (r2.0.8). Figure prepared
with HaploView (Barrett et al. 2005).
doi:10.1371/journal.pone.0064872.g003
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volumes was not limited to, or greater in, patients with
schizophrenia is in line with the intermediate phenotype hypoth-
esis. Using intermediate phenotypes allows for the identification of
risk alleles in individuals who do not carry a diagnosis (i.e. healthy
controls, siblings or individuals with subthreshold symptoms)
assuming that the liability to schizophrenia is stochastic rather
than categorical. However, our study cannot answer the question
whether the association between the identified SNPs and
hippocampal volume is specific to schizophrenia but it has been
suggested that a variety of other polymorphisms with small effect
sizes, reciprocal effects with risk alleles of other genes, copy
number variants and environmental influences may constitute a
background of risk factors that could interact with the effects of
NR2F6, USHBP1 and BABAM1 to increase schizophrenia suscep-
tibility. This susceptibility may manifest itself, in part, as a
structural change in the medial temporal lobe [64–66].
Follow up studies should not only replicate our findings but also
relate the identified variants to cognitive or functional markers
relevant to neuropsychiatric disorders. We attempted to take a first
step into this direction by relating the polymorphisms in the
NR2F6, USHBP1, and BABAM1 genes - although not genome-
wide significant - to hippocampus-dependent cognitive functions,
most importantly, verbal and logical memory [67–69]. Indeed, our
exploratory structural equation models provide additional evi-
dence for an association between the risk SNPs in these genes and
impaired memory functioning which was mediated by reduced
hippocampal volumes (see Table S6 and Figure S3 in File S1). In
support of our findings, histopathological studies have indicated a
causal relationship between verbal memory impairments and
hippocampal neuron loss in CA3 and the hilar area for patients
with left temporal seizure foci [70,71].
The four remaining SNPs rs9919234, rs11901004, rs17866592,
and rs1254152 (see Table 2) belong to KIF26B (1q44), TRPM8
(2q37.1) and an uncharacterized gene region (LOC283089,
10q26.13), respectively. Intervals in 1q44 have been described as
critical regions containing genes leading to structural abnormal-
ities of the corpus callosum [72]. The transient receptor potential
(TRP) superfamily comprises a group of non-selective cation
channels that sense and respond to changes in their local
environments. In the central nervous system, TRPs participate
in neurite outgrowth, receptor signalling and excitotoxic cell death
resulting from anoxia [73]. Accordingly, TRPM8 was found to be
a susceptibility loci for common migraine and has been the focus
of neuropathic pain models [74].
Previous imaging genetics studies on hippocampal atrophy
using a genome-wide approach have all focused on Alzheimer’s
disease. All three studies [40,75,76] are largely based on the same
sample obtained via the multicenter Alzheimer’s Disease Neuro-
imaging Initiative [77]. Potkin et al. (2009) used hippocampal grey
matter density as intermediate phenotype and identified suscep-
tibility genes for Alzheimer’s disease by analyzing interaction
effects. Shen et al. (2010) included a variety of imaging phenotypes
(grey matter density and volumetric measures) but did not
replicate the initial findings. It was concluded, that different
imaging phenotypes (i.e. regions and grey matter density vs.
volumes) may not be equally sensitive to the same genetic markers
and consequently provide complementary information. Finally
Furney et al. (2011) found a disease-specific effect of ZNF292 on
entorhinal cortex volume which reached genome-wide signifi-
cance. Our study design was different from these reports in that we
focussed on hippocampal volume and used an independent sample
of patients with schizophrenia and healthy controls.
Very recently the ENIGMA consortium published a genome-
wide association analysis for mean bilateral hippocampal, total
brain and intracranial volume [20]. In a large discovery sample
no markers reached genome-wide significance and previously
identified polymorphisms associated with hippocampal volume or
schizophrenia showed no or little association. The strongest
association signal for hippocampal volume after controlling for
intracranial volume was reported for two SNPs in the same LD
block (rs7294919 and rs7315280 with p = 4.4361027 and
p = 2.4261027, respectively), located between HRK and FBXW8
(12q24.22). Neither SNP reached genome-wide significance in
our sample (p = 0.05565 and p = 0.007548, respectively) or in any
of the other studies on the genetics of hippocampal volume
described above. Possible reasons for the different main results of
the ENIGMA study compared to our own GWAS results
comprise the different study design and cohorts (i.e. ENIGMA
combined 17 European cohorts, some of them multicentre
studies, and the data was obtained using different MRI scanner
and MRI data analysis technologies as well as different
genotyping platforms across the acquisition sites) as well as a
somewhat different statistical approach (i.e. their models included
other covariates).
Although the main association signals of the ENIGMA and our
own study do not correspond, our in silico replication approach
using data from the ENIGMA study provides supportive evidence
for the validity of our own association signals. Similarly the
regression models using genetic and hippocampal volume data of
the IMAGEN study revealed SNPs in close proximity to our main
hits which were associated with hippocampal volume. Given that
the IMAGEN study includes solely 14-year olds, these results
indicate that the identified genes or gene regions might exert their
influence on hippocampal volume during development.
Nevertheless, the findings of our study have to be considered
in the light of the following limitations. Firstly, none of the
identified risk variants did reach the commonly accepted
genome-wide significance threshold. Our sample set was limited
by the number of individuals with genetic information but the
use of a quantitative trait design has been shown to substantially
increase the statistical power [78]. The fact that six SNPs in
strong LD exhibited near-threshold association is encouraging
and suggests that our findings were not likely due to genotyping
artifact, although the effects may be small. Additionally,
validation in a more homogeneous subsample of European
descent as well as the gene expression and cognitive functioning
analysis lend further support to the relevance of the identified
loci. Secondly, the replication data sets did not include equally
large numbers of schizophrenia patients (none in the IMAGEN
sample) which makes it difficult to compare results and also
precludes answering the question whether our findings are
specific to schizophrenia. Thirdly, the differential allelic
expression analysis was carried out using tissue of patients with
chronic pharmacoresistent temporal lobe epilepsy. Although
possibly more reliable than using post mortem brain tissue,
epilepsy may affect non-coding DNA regulatory elements in
some cells in a different way than schizophrenia or at-risk states
for schizophrenia [79]. Finally, although the pattern of our
results seems to point to developmental mechanisms, the
hippocampus is subject to a variety of environmental influences
such as physical exercise or stress effects mediated by the HPA
[80,81]. Such effects could either blur earlier developmental
effects or they could themselves be moderated by genetic
polymorphisms or epigenetic mechanisms [82]. To disentangle
these complicated relationships, gene-environment interaction
studies are warranted – unfortunately our study did not include
any measures of stress or cortisol levels.
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Conclusions
Taken together, our findings support previous reports demon-
strating that GWAS with a quantitative brain-based intermediate
phenotype as a dependent variable is a viable method to identify
associated gene variants without making prior assumptions about
the underlying biology of the phenotype. Our results were
supported by gene expression, cognitive data and similar
association signals in the replication samples. Elucidating the
specific mechanisms of NR2F6, USHBP1 and BABAM1 in the
regulation of neurodevelopment and synaptic (re)organization
could improve our conceptual framework of processes related to
hippocampal volume reduction and facilitate a better understand-
ing of schizophrenia. Ultimately, imaging genetics could contrib-
ute to the development of methods for earlier detection and
tailored therapeutic intervention in schizophrenia and other
neuropsychiatric disorders [83].
Supporting Information
File S1 SI 1 Material and Methods, SI 2 Results.
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Figure S1 First two principal components (PC) plotted
against each other for MCIC data and the four HapMap
populations. Definition of European subsample as described
above (zoomed in on the right picture). Blue cross marks the center
of all HapMap CEU individuals (International HapMap Project
http://www.hapmap.org/). Blue circles are the single (inner circle)
and 1.5 times (outer circle) the Euclidean distance between this
center and the HapMap CEU individual farthest away from this
center.
(TIF)
Figure S2 Forest plot of regression coefficients and
corresponding 95% confidence intervals for main hits in
the patient group and in healthy controls, respectively
(MCIC sample). SZ = patients with schizophrenia;
HC = healthy controls.
(TIF)
Figure S3 Path model predicting indirect effects of SNP
on memory. Standardized path coefficients are given exemplar-
ily for SNP rs35686037. Indirect effect of marker rs35686037 on
‘‘Memory’’ =20.047 in the MCIC sample. For all other values see
Table S4 in File S1. E1 to e5 are error terms.
(TIF)
Figure S4 Expression of NR2F6 in human hippocam-
pus. Hippocampal formation spatially shown in green. Red
diamonds represent loci of higher expression compared to other
tissues. Figure prepared with Allen Human Brain Atlas – Brain Explorer
2 (Version 2.2 Build 2312) of the Allen Institute for Brain Science
(Lau et al., 2008).
(TIF)
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